Candel Therapeutics Inc Aktie News

Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. The RMAT designation is intended to expedite the development and review ...

NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (...

NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Com...

Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present results from its positive Phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3 in Chicago. “We are honored that our pivotal phase 3 CAN-2409 data will be presented at the ASCO Annual Meeting, reinforcing ...

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company's positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate...

Candel Therapeutics Inc (NASDAQ:CADL) reported a quarterly profit and said it remains on track to submit a biologics license application (BLA) in late 2026 for its lead cancer therapy, CAN-2409, aimed at treating localized prostate cancer. The clinical-stage biotech posted net income of $7.4 million for the first quarter ended March 31, compared with a net loss of $8.2 million a year earlier, h...